Biohaven FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Biohaven Ltd. (NYSE:BHVN) – Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Biohaven in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn ($6.80) per share for the year, down from their prior estimate of ($6.05). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($8.90) per share.

Other equities research analysts have also issued reports about the company. JPMorgan Chase & Co. decreased their price target on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $54.00 target price on shares of Biohaven in a research note on Tuesday. Deutsche Bank Aktiengesellschaft started coverage on shares of Biohaven in a research report on Tuesday, February 11th. They set a “buy” rating and a $65.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a research report on Tuesday. Finally, TD Cowen upped their target price on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $62.77.

Biohaven Stock Down 1.9 %

NYSE:BHVN opened at $30.37 on Thursday. The firm has a market cap of $3.07 billion, a PE ratio of -3.25 and a beta of 1.27. The company’s 50-day moving average price is $37.98 and its two-hundred day moving average price is $42.58. Biohaven has a 12 month low of $26.80 and a 12 month high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29).

Hedge Funds Weigh In On Biohaven

A number of hedge funds and other institutional investors have recently made changes to their positions in BHVN. Vanguard Group Inc. raised its stake in Biohaven by 8.1% during the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company’s stock worth $314,267,000 after buying an additional 628,211 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Biohaven by 12.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company’s stock worth $260,735,000 after acquiring an additional 756,032 shares in the last quarter. Stifel Financial Corp raised its position in shares of Biohaven by 0.8% during the fourth quarter. Stifel Financial Corp now owns 6,559,313 shares of the company’s stock worth $244,990,000 after purchasing an additional 50,052 shares during the period. Suvretta Capital Management LLC lifted its holdings in shares of Biohaven by 8.1% during the 4th quarter. Suvretta Capital Management LLC now owns 5,620,271 shares of the company’s stock valued at $209,917,000 after purchasing an additional 421,052 shares in the last quarter. Finally, Farallon Capital Management LLC increased its stake in Biohaven by 21.6% during the 4th quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company’s stock worth $165,392,000 after purchasing an additional 785,578 shares in the last quarter. 88.78% of the stock is owned by institutional investors.

Insider Transactions at Biohaven

In other news, Director John W. Childs acquired 32,700 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 16.00% of the stock is owned by corporate insiders.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.